VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+4.9%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$265M
AUM Growth
+$37.5M
(+17%)
Cap. Flow
+$31.7M
Cap. Flow
% of AUM
11.98%
Top 10 Holdings %
Top 10 Hldgs %
9.25%
Holding
421
New
24
Increased
206
Reduced
145
Closed
45
Top Buys
| 1 |
DT Midstream
DTM
|
$1.86M |
| 2 |
ScottsMiracle-Gro
SMG
|
$878K |
| 3 |
Valero Energy
VLO
|
$790K |
| 4 |
FMC
FMC
|
$775K |
| 5 |
Delek US
DK
|
$761K |
Top Sells
| 1 |
COR
Coresite Realty Corporation
COR
|
$1.67M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$601K |
| 3 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
$551K |
| 4 |
Travere Therapeutics
TVTX
|
$479K |
| 5 |
KDMN
Kadmon Holdings, Inc.
KDMN
|
$448K |
Sector Composition
| 1 | Real Estate | 22.39% |
| 2 | Healthcare | 18.38% |
| 3 | Energy | 15.88% |
| 4 | Materials | 14.07% |
| 5 | Utilities | 13.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Incyte
INCY
$16.8B
| $398K | 0.15% |
5,423
-113
| -2% | -$8.29K |
|
|
SGEN
152
DELISTED
Seagen Inc. Common Stock
SGEN
| $398K | 0.15% |
2,575
-350
| -12% | -$54.1K |
|
153
Ironwood Pharmaceuticals
IRWD
$180M
| $397K | 0.15% |
34,062
-6,633
| -16% | -$77.3K |
|
154
BioMarin Pharmaceuticals
BMRN
$10.9B
| $396K | 0.15% |
4,486
-1,058
| -19% | -$93.4K |
|
155
Nektar Therapeutics
NKTR
$614M
| $396K | 0.15% |
1,956
+232
| +13% | +$47K |
|
|
EFR
156
Eaton Vance Senior Floating-Rate Fund
EFR
$344M
| $394K | 0.15% |
26,680
-5,643
| -17% | -$83.3K |
|
157
Amgen
AMGN
$152B
| $391K | 0.15% |
1,740
-151
| -8% | -$33.9K |
|
158
Sarepta Therapeutics
SRPT
$1.91B
| $391K | 0.15% |
4,345
-966
| -18% | -$86.9K |
|
159
Vertex Pharmaceuticals
VRTX
$102B
| $390K | 0.15% |
1,778
-572
| -24% | -$125K |
|
160
Oaktree Specialty Lending
OCSL
$1.21B
| $389K | 0.15% |
17,369
-1,412
| -8% | -$31.6K |
|
161
ADC Therapeutics
ADCT
$359M
| $388K | 0.15% |
19,193
-535
| -3% | -$10.8K |
|
162
Biogen
BIIB
$20.2B
| $387K | 0.15% |
1,612
+481
| +43% | +$115K |
|
|
EFT
163
Eaton Vance Floating-Rate Income Trust
EFT
$320M
| $386K | 0.15% |
25,578
-3,618
| -12% | -$54.6K |
|
|
EVF
164
Eaton Vance Senior Income Trust
EVF
$101M
| $385K | 0.15% |
57,103
-4,521
| -7% | -$30.5K |
|
165
Invesco Senior Income Trust
VVR
$555M
| $385K | 0.15% |
88,956
-13,742
| -13% | -$59.5K |
|
166
Gilead Sciences
GILD
$140B
| $383K | 0.14% |
5,274
-1,436
| -21% | -$104K |
|
167
Neurocrine Biosciences
NBIX
$13.6B
| $383K | 0.14% |
4,497
-97
| -2% | -$8.26K |
|
168
Ultragenyx Pharmaceutical
RARE
$3.01B
| $383K | 0.14% |
4,550
+100
| +2% | +$8.42K |
|
169
Y-mAbs Therapeutics
YMAB
$389M
| $383K | 0.14% |
23,646
+11,068
| +88% | +$179K |
|
170
Agios Pharmaceuticals
AGIO
$2.04B
| $379K | 0.14% |
11,541
+3,692
| +47% | +$121K |
|
171
Insmed
INSM
$29.9B
| $378K | 0.14% |
13,869
-1,392
| -9% | -$37.9K |
|
172
Acadia Pharmaceuticals
ACAD
$4.31B
| $377K | 0.14% |
16,172
-613
| -4% | -$14.3K |
|
173
Ionis Pharmaceuticals
IONS
$9.46B
| $374K | 0.14% |
12,296
+194
| +2% | +$5.9K |
|
174
Zai Lab
ZLAB
$3.3B
| $373K | 0.14% |
5,933
+3,241
| +120% | +$204K |
|
175
Barings BDC
BBDC
$979M
| $367K | 0.14% |
33,326
-1,625
| -5% | -$17.9K |
|